Complex analysis of the TP53 tumor suppressor in mantle cell
and diffuse large B-cell lymphomas

J 2017

Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas

ZLÁMALÍKOVÁ, Lenka, Mojmír MOULIS, Barbora RAVČUKOVÁ, Květoslava LIŠKOVÁ, Jitka MALČÍKOVÁ et. al.

Základní údaje

Originální název

Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas

Autoři

ZLÁMALÍKOVÁ, Lenka (203 Česká republika), Mojmír MOULIS (203 Česká republika), Barbora RAVČUKOVÁ (203 Česká republika), Květoslava LIŠKOVÁ (203 Česká republika), Jitka MALČÍKOVÁ (203 Česká republika), David ŠÁLEK (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, garant, domácí), Miluše SVITÁKOVÁ (203 Česká republika), Renata HRABÁLKOVÁ (203 Česká republika), Jan ŠMARDA (203 Česká republika) a Jana ŠMARDOVÁ (203 Česká republika)

Vydání

Oncology Reports, ATHENS, SPANDIDOS PUBL LTD, 2017, 1021-335X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.976

Kód RIV

RIV/00216224:14110/17:00097935

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3892/or.2017.5891

UT WoS

000411688200073

Klíčová slova anglicky

mantle cell lymphoma; diffuse large B-cell lymphoma; p53 tumor suppressor; FASAY; TP53 mutation

Štítky

EL OK, podil

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 18. 3. 2018 15:22, Soňa Böhmová

Anotace

V originále

Mutations and deletions of the tumor suppressor TP53 gene are the most frequent genetic alterations detected in human tumors, though they are rather less frequent in lymphomas. However, acquisition of the TP53 mutation was demonstrated to be one of the characteristic markers in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) and prognostic value of the TP53 status has been recognized for these diseases. We present the complex analysis of the TP53 aberrations in 57 cases of MCL and 131 cases of DLBCL. The TP53 status was determined by functional analyses in yeast (FASAY) followed by cDNA and gDNA sequencing. The level of the p53 protein was assessed by immunoblotting and loss of the TP53-specific locus 17p13.3 was detected by FISH. Altogether, we detected 13 TP53 mutations among MCL cases (22.8%) and 29 TP53 mutations in 26 from 131 DLBCL cases (19.8%). The ratio of missense TP53 mutations was 76.9% in MCL and 82.8% in DLBCL. The frequency of TP53 locus deletion was rather low in both diseases, reaching 9.3% in MCL and 15.3% in DLBCL. The presence of TP53 mutation was associated with shorter overall survival (OS) and progression-free survival (PFS) in MCL. Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

Citovat

ZLÁMALÍKOVÁ, Lenka, Mojmír MOULIS, Barbora RAVČUKOVÁ, Květoslava LIŠKOVÁ, Jitka MALČÍKOVÁ, David ŠÁLEK, Jiří JARKOVSKÝ, Miluše SVITÁKOVÁ, Renata HRABÁLKOVÁ, Jan ŠMARDA a Jana ŠMARDOVÁ. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. Oncology Reports. ATHENS: SPANDIDOS PUBL LTD, 2017, roč. 38, č. 4, s. 2535-2542. ISSN 1021-335X. Dostupné z: https://dx.doi.org/10.3892/or.2017.5891.

@article{1392780,
   author = {Zlámalíková, Lenka and Moulis, Mojmír and Ravčuková, Barbora and Lišková, Květoslava and Malčíková, Jitka and Šálek, David and Jarkovský, Jiří and Svitáková, Miluše and Hrabálková, Renata and Šmarda, Jan and Šmardová, Jana},
   article_location = {ATHENS},
   article_number = {4},
   doi = {http://dx.doi.org/10.3892/or.2017.5891},
   keywords = {mantle cell lymphoma; diffuse large B-cell lymphoma; p53 tumor suppressor; FASAY; TP53 mutation},
   language = {eng},
   issn = {1021-335X},
   journal = {Oncology Reports},
   title = {Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas},
   url = {https://www.spandidos-publications.com/10.3892/or.2017.5891},
   volume = {38},
   year = {2017}
}

TY  - JOUR
ID  - 1392780
AU  - Zlámalíková, Lenka - Moulis, Mojmír - Ravčuková, Barbora - Lišková, Květoslava - Malčíková, Jitka - Šálek, David - Jarkovský, Jiří - Svitáková, Miluše - Hrabálková, Renata - Šmarda, Jan - Šmardová, Jana
PY  - 2017
TI  - Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas
JF  - Oncology Reports
VL  - 38
IS  - 4
SP  - 2535-2542
EP  - 2535-2542
PB  - SPANDIDOS PUBL LTD
SN  - 1021335X
KW  - mantle cell lymphoma
KW  - diffuse large B-cell lymphoma
KW  - p53 tumor suppressor
KW  - FASAY
KW  - TP53 mutation
UR  - https://www.spandidos-publications.com/10.3892/or.2017.5891
N2  - Mutations and deletions of the tumor suppressor TP53 gene are the most frequent genetic alterations detected in human tumors, though they are rather less frequent in lymphomas. However, acquisition of the TP53 mutation was demonstrated to be one of the characteristic markers in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) and prognostic value of the TP53 status has been recognized for these diseases. We present the complex analysis of the TP53 aberrations in 57 cases of MCL and 131 cases of DLBCL. The TP53 status was determined by functional analyses in yeast (FASAY) followed by cDNA and gDNA sequencing. The level of the p53 protein was assessed by immunoblotting and loss of the TP53-specific locus 17p13.3 was detected by FISH. Altogether, we detected 13 TP53 mutations among MCL cases (22.8%) and 29 TP53 mutations in 26 from 131 DLBCL cases (19.8%). The ratio of missense TP53 mutations was 76.9% in MCL and 82.8% in DLBCL. The frequency of TP53 locus deletion was rather low in both diseases, reaching 9.3% in MCL and 15.3% in DLBCL. The presence of TP53 mutation was associated with shorter overall survival (OS) and progression-free survival (PFS) in MCL. Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease.
ER  -

ZLÁMALÍKOVÁ, Lenka, Mojmír MOULIS, Barbora RAVČUKOVÁ, Květoslava LIŠKOVÁ, Jitka MALČÍKOVÁ, David ŠÁLEK, Jiří JARKOVSKÝ, Miluše SVITÁKOVÁ, Renata HRABÁLKOVÁ, Jan ŠMARDA a Jana ŠMARDOVÁ. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. \textit{Oncology Reports}. ATHENS: SPANDIDOS PUBL LTD, 2017, roč.~38, č.~4, s.~2535-2542. ISSN~1021-335X. Dostupné z: https://dx.doi.org/10.3892/or.2017.5891.

Podrobný výpis o publikaci